TherapeuticsMD Inc (NASDAQ:TXMD) CEO Robert G. Finizio bought 35,000 shares of the stock in a transaction dated Tuesday, August 20th. The stock was purchased at an average cost of $2.74 per share, for a total transaction of $95,900.00. Following the acquisition, the chief executive officer now owns 18,253,964 shares of the company’s stock, valued at $50,015,861.36. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
TXMD traded down $0.08 during midday trading on Tuesday, reaching $2.74. 4,711,019 shares of the company’s stock were exchanged, compared to its average volume of 3,274,722. The company has a debt-to-equity ratio of 24.29, a current ratio of 5.17 and a quick ratio of 4.99. The stock has a market capitalization of $689.89 million, a PE ratio of -4.64 and a beta of 1.90. The business’s 50-day moving average price is $2.48 and its 200 day moving average price is $3.87. TherapeuticsMD Inc has a 1-year low of $1.82 and a 1-year high of $6.94.
TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Tuesday, August 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The business had revenue of $6.08 million for the quarter, compared to analyst estimates of $5.12 million. TherapeuticsMD had a negative return on equity of 212.57% and a negative net margin of 913.07%. The business’s revenue was up 60.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.15) EPS. As a group, analysts expect that TherapeuticsMD Inc will post -0.73 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the company. Private Ocean LLC purchased a new stake in TherapeuticsMD during the first quarter worth approximately $37,000. Moors & Cabot Inc. purchased a new position in shares of TherapeuticsMD in the second quarter valued at $25,000. Moloney Securities Asset Management LLC purchased a new position in shares of TherapeuticsMD in the second quarter valued at $27,000. Highland Private Wealth Management purchased a new position in shares of TherapeuticsMD in the second quarter valued at $28,000. Finally, Menta Capital LLC purchased a new position in shares of TherapeuticsMD in the first quarter valued at $56,000. 81.05% of the stock is owned by institutional investors and hedge funds.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Featured Story: How to identify percentage decliners
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.